The Phase 3 program includes trials in obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH)
Ozempic is not recommended during pregnancy or breastfeeding
Combination likely superior to either alone addressing both immediate oxidative stress and enhancing cellular defenses
A 24-week athlete study found collagen hydrolysate reduced activity-related joint pain in athletes with functional knee problems
Identifying GLP-1 Non-Responders Early in Treatment Early identification of patients who may not respond adequately to GLP-1 receptor agonist therapy represents a critical step in optimizing obesity treatment pathways
One recent study, which included about 3,094 men without diabetes living with obesity between ages 18-50 who received semaglutide, found a relationship between semaglutide and decreased testosterone levels